Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2016-07-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1568026616666160216155556PMID 26881709
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.

  2015cited by this paper
• Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

  2015cited by this paper
• Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors.

  2015cited by this paper
• Evolutions in fragment-based drug design: the deconstruction-reconstruction approach.

  2015cited by this paper
• Computational drug repositioning for cancer therapeutics.

  2015cited by this paper
• Small molecules, peptides and natural products: getting a grip on 14-3-3 protein-protein modulation.

  2014cited by this paper
• Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.

  2014cited by this paper
• Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors.

  2014cited by this paper
• Acetazolamide triggers death inducing autophagy in T‐47D breast cancer cells

  2014cited by this paper
• Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.

  2014cited by this paper
• Clinical development success rates for investigational drugs

  2014cited by this paper
• Alternative approaches to Hsp90 modulation for the treatment of cancer.

  2014cited by this paper
• Polypharmacology: challenges and opportunities in drug discovery.

  2014cited by this paper
• What do drug transporters really do?

  2014cited by this paper
• Sulindac-derived RXRα modulators inhibit cancer cell growth by binding to a novel site.

  2014cited by this paper
• Identification of a new scaffold for hsp90 C-terminal inhibition.

  2014cited by this paper
• Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.

  2014cited by this paper
• Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs

  2014cited by this paper
• Stable overexpression of DNA fragmentation factor in T-47D cells: sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide

  2014cited by this paper
• Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3).

  2014cited by this paper
• Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.

  2013cited by this paper
• Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase.

  2013cited by this paper
• Structural basis for the drug extrusion mechanism by a MATE multidrug transporter

  2013cited by this paper
• A Combined Bioinformatics and Chemoinformatics Approach for Developing Asymmetric Bivalent AMPA Receptor Positive Allosteric Modulators as Neuroprotective Agents

  2013cited by this paper
• Update on Raloxifene: Mechanism of Action, Clinical Efficacy, Adverse Effects, and Contraindications

  2013cited by this paper
• Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells.

  2013cited by this paper
• Inhibition of HSP90 molecular chaperones: moving into the clinic.

  2013cited by this paper
• Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.

  2013cited by this paper
• Small-molecule modulators of 14-3-3 protein-protein interactions.

  2013cited by this paper
• Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.

  2013cited by this paper
• Small molecules modulation of 14-3-3 protein-protein interactions.

  2013cited by this paper
• Effect of incorporating a thiophene tail in the scaffold of acetazolamide on the inhibition of human carbonic anhydrase isoforms I, II, IX and XII.

  2013cited by this paper
• Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.

  2012cited by this paper
• Advances in drug design with RXR modulators

  2012cited by this paper
• Synthesis of novel 2-mercapto benzothiazole and 1,2,3-triazole based bis-heterocycles: their anti-inflammatory and anti-nociceptive activities.

  2012cited by this paper
• Anticancer drug design using scaffolds of β-lactams, sulfonamides, quinoline, quinoxaline and natural products. Drugs advances in clinical trials.

  2012cited by this paper
• Predicting new indications for approved drugs using a proteochemometric method.

  2012cited by this paper
• Recent advances in medicinal chemistry of sulfonamides. Rational design as anti-tumoral, anti-bacterial and anti-inflammatory agents.

  2012cited by this paper
• Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

  2012cited by this paper
• 14-3-3 zeta as novel molecular target for cancer therapy

  2012cited by this paper
• Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?

  2012cited by this paper
• Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties.

  2012cited by this paper
• Acetazolamide inhibits aquaporin-1 expression and colon cancer xenograft tumor growth.

  2011cited by this paper
• Long-term raloxifene for postmenopausal osteoporosis

  2011cited by this paper
• 14-3-3 proteins as potential therapeutic targets.

  2011cited by this paper
• Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor

  2011cited by this paper
• Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins

  2011cited by this paper
• Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.

  2011cited by this paper
• Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.

  2010cited by this paper
• Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

  2010cited by this paper
• CH05‐10, a novel indinavir analog, is a broad‐spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy

  2010cited by this paper
• NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.

  2010cited by this paper
• In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.

  2009cited by this paper
• A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity

  2009cited by this paper
• Anti-HIV drugs for cancer therapeutics: back to the future?

  2009cited by this paper
• A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.

  2009cited by this paper
• Predicting new molecular targets for known drugs

  2009cited by this paper
• Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis.

  2009cited by this paper
• Raloxifene in breast cancer prevention.

  2008cited by this paper
• Drug Target Identification Using Side-Effect Similarity

  2008cited by this paper
• Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

  2008cited by this paper
• Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

  2008cited by this paper
• A decade of fragment-based drug design: strategic advances and lessons learned

  2007cited by this paper
• New uses for old drugs

  2007cited by this paper
• Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation

  2006cited by this paper
• Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.

  2006cited by this paper
• Evaluation of Antitumoral Properties of the Protease Inhibitor Indinavir in a Murine Model of Hepatocarcinoma

  2006cited by this paper
• Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus

  2006cited by this paper
• Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines

  2005cited by this paper
• Hsp90 inhibitors identified from a library of novobiocin analogues.

  2005cited by this paper
• A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

  2004cited by this paper
• Drug repositioning: identifying and developing new uses for existing drugs

  2004cited by this paper
• Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

  2004cited by this paper
• Acetazolamide inhibits aquaporin-1 protein expression and angiogenesis.

  2004cited by this paper
• Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs

  2003cited by this paper
• Sulindac and its derivatives: a novel class of anticancer agents.

  2001cited by this paper
• Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells

  2001cited by this paper
• THE EFFICACY OF ACETAZOLAMIDE ON VISUAL FUNCTIONS IN A PATIENT WITH CHOROID METASTASIS OF BREAST CARCINOMA

  2001cited by this paper
• Effects of nimesulide and its reduced metabolite on mitochondria

  2000cited by this paper
• Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.

  2000cited by this paper
• Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.

  2000cited by this paper
• The Nobel chronicles. 1985: Joseph Leonard Goldstein (b 1940), Michael Stuart Brown (b 1941).

  2000cited by this paper
• The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone*

  2000cited by this paper
• The Nobel chronicles. 1946: Hermann Joseph Muller (1890-1967).

  1999cited by this paper

• Crystallographic fragment screening reveals new starting points for PYCR1 inhibitor design.

  2025cites this paper
• Targeting EGFR/PI3K/AKT/mTOR and Bax/Bcl-2/caspase3 pathways with ivermectin mediates its anticancer effects against urethane-induced non-small cell lung cancer in BALB/c mice.

  2025cites this paper
• Identification of imidazo[1,2-a]pyridine-3-amine as a novel drug-like scaffold for efficious ferroptosis inhibition in vivo.

  2025cites this paper
• Repurposing bosentan as an anticancer agent: EGFR/ERK/c‐Jun modulation inhibits NSCLC tumor growth

  2025cites this paper
• Venlafaxine suppressed PD-L1 expression through oxidative stress and improved anti-tumor immune responses in melanoma mice.

  2025cites this paper
• Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action

  2024cites this paper
• Methimazole and α-lipoic acid as metallo-β-lactamases inhibitors

  2022cites this paper
• Beethoven and Divergent Thinking

  2022cites this paper
• Privileged Scaffolds Targeting Bromodomain-containing Protein 4.

  2022cites this paper
• Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors.

  2021cites this paper
• Pathway-Based Drug-Repurposing Schemes in Cancer: The Role of Translational Bioinformatics

  2021cites this paper
• A personalized medicine approach to drug repurposing for the treatment of breast cancer molecular subtypes

  2020cites this paper
• AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia.

  2020cites this paper
• Identification of drug candidates for breast cancer therapy through scaffold repurposing: A brief review.

  2020cites this paper
• Repurposing of Benzimidazole Scaffolds for HER-2 Positive Breast Cancer Therapy: An In-Silico Approach.

  2020cites this paper
• Clinical trials on combination of repurposed drugs and anticancer therapies

  2020cites this paper
• Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria

  2019cites this paper
• Drug Repurposing in the Development of Anticancer Agents.

  2019cites this paper
• Repurposing of plant alkaloids for cancer therapy: Pharmacology and toxicology.

  2019cites this paper
• Structural basis of methotrexate and pemetrexed action on serine hydroxymethyltransferases revealed using plant models

  2019cites this paper
• A. thaliana serine hydroxymethyltransferase isoform 2 (AtSHMT2) in complex with pemetrexed

  2019cites this paper
• Rhenium Sulfide Nanoparticles as a Biosafe Spectral CT Contrast Agent for Gastrointestinal Tract Imaging and Tumor Theranostics in vivo.

  2019cites this paper
• Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer.

  2018cites this paper
• Structure activity relationships of chrysoeriol and analogs as dual c ‐ Met and VEGFR 2 tyrosine kinase inhibitors

  2018cites this paper
• Synthesis and Characterization of a Biomimetic Formulation of Clofazimine Hydrochloride Microcrystals for Parenteral Administration

  2018cites this paper
• Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response

  2018cites this paper
• One-pot synthesis of tricyclo-1,4-benzoxazines via visible-light photoredox catalysis in continuous flow

  2017cites this paper
• Acetic Acid Accelerated Visible-Light Photoredox Catalyzed N-Demethylation of N,N-Dimethylaminophenyl Derivatives

  2017cites this paper